CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Trial Details

NCT ID

NCT05143996

Phase

PHASE1 / PHASE2

Sponsor

Cullinan Therapeutics Inc.

Status

RECRUITING

Cancer Type

Leukemia

Interventions

• CLN-049

Locations (sample)

• Birmingham, Alabama, United States|33.52066,-86.80249
• Phoenix, Arizona, United States|33.44838,-112.07404
• Duarte, California, United States|34.13945,-117.97729
• Los Angeles, California, United States|34.05223,-118.24368
• Aurora, Colorado, United States|39.72943,-104.83192

Key Eligibility Criteria

• Aged ≥ 18 years of age.
• Patient has a confirmed diagnosis of recurrent or refractory AML or MDS:
• Parts A, B, C:
• i. AML either de novo or secondary ii. MDS with at least 5% blasts that is relapsed after or refractory to hypomethylating agent (HMA) therapy iii.…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.